{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:01:10Z","timestamp":1784930470477,"version":"3.55.0"},"reference-count":45,"publisher":"Informa UK Limited","issue":"32","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["213368"],"award-info":[{"award-number":["213368"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.2217\/fon-2022-0348","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T15:39:36Z","timestamp":1668785976000},"page":"3651-3665","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond)"],"prefix":"10.1080","volume":"18","author":[{"given":"Charlotte","family":"Carroll","sequence":"first","affiliation":[{"name":"Value Evidence &amp; Outcomes,GSK,\rCollegeville,\rPA 19426,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashita","family":"Patel","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development,GSK,\rStevenage,\rHertfordshire,\rSG1 2NY,\rUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1298-2462","authenticated-orcid":false,"given":"Necdet B","family":"Gunsoy","sequence":"additional","affiliation":[{"name":"Value Evidence &amp; Outcomes,GSK,\rUxbridge,\rMiddlesex,\rUB11 1BT,\rUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0734-0422","authenticated-orcid":false,"given":"Heide A","family":"Stirnadel-Farrant","sequence":"additional","affiliation":[{"name":"Value Evidence &amp; Outcomes,GSK,\rStevenage,\rHertfordshire,\rSG1 2NY,\rUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-4317","authenticated-orcid":false,"given":"Shibani","family":"Pokras","sequence":"additional","affiliation":[{"name":"Value Evidence &amp; Outcomes,GSK,\rCollegeville,\rPA 19426,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21442"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5467057"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.17349"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/COAYA.S91024"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz283.061"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.e22535"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24370"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e23576"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-018-0525-1"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10110417"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3039"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-2622"},{"key":"e_1_3_6_15_1","unstructured":"European Medicines Agency\n. Votrient (pazopanib) (2021). www.ema.europa.eu\/en\/medicines\/human\/EPAR\/votrient (Accessed 3September2021)."},{"key":"e_1_3_6_16_1","unstructured":"Food and Drug Administration\n. Votrient (pazopanib) (2021). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022465s-010S-012lbl.pdf (Accessed 3September2021)."},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60651-5"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.117"},{"key":"e_1_3_6_19_1","unstructured":"Food and Drug Administration\n. Yondelis (trabectedin) (2021). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207953s005lbl.pdf (Accessed 3September2021)."},{"key":"e_1_3_6_20_1","unstructured":"European Medicines Agency\n. Yondelis (trabectedin) (2021). www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu301039 (Accessed 3September2021)."},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4734"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70098-7"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.05.012"},{"key":"e_1_3_6_24_1","first-page":"925","article-title":"More than 50 subtypes of soft tissue sarcoma: paving the path for histology-driven treatments. American Society of Clinical Oncology educational book","volume":"38","author":"Katz D","year":"2018","unstructured":"Katz D , PalmeriniE, PollackSM. More than 50 subtypes of soft tissue sarcoma: paving the path for histology-driven treatments. American Society of Clinical Oncology educational book. American Society of Clinical Oncology Annual Meeting38, 925\u2013938 (2018).","journal-title":"American Society of Clinical Oncology Annual Meeting"},{"key":"e_1_3_6_25_1","first-page":"1a","article-title":"Challenges of using ICD-9-CM and ICD-10-CM codes for soft-tissue sarcoma in databases for health services research","volume":"16","author":"Hess LM","year":"2019","unstructured":"Hess LM , ZhuYE, SugiharaT, FangY, CollinsN, NicolS. Challenges of using ICD-9-CM and ICD-10-CM codes for soft-tissue sarcoma in databases for health services research. Perspect. Health Inf. Manag.16(Spring), 1a (2019).","journal-title":"Perspect. Health Inf. Manag."},{"key":"e_1_3_6_26_1","unstructured":"US FDA\n (2022). www.fda.gov\/ (Accessed 14September2021)."},{"key":"e_1_3_6_27_1","unstructured":"EMA\n (2022). www.ema.europa.eu\/en (Accessed 14September2021)."},{"key":"e_1_3_6_28_1","unstructured":"National Institute for Health and Care Excellence\n (2022). www.nice.org.uk\/ (Accessed 14September2021)."},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijc.IJC_169_17"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3223"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2017.1332779"},{"issue":"3","key":"e_1_3_6_32_1","first-page":"48","article-title":"Real-world experiences with pazopanib in patients with advanced soft tissue and bone sarcoma in northern California","volume":"7","author":"Seto T","year":"2019","unstructured":"Seto T , SongMN, TrieuMet al. Real-world experiences with pazopanib in patients with advanced soft tissue and bone sarcoma in northern California. Med. Sci. (Basel)7(3), 48 (2019).","journal-title":"Med. Sci. (Basel)"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy299.040"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1160-x"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-64"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.210"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.12.014"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.10030"},{"issue":"6","key":"e_1_3_6_39_1","first-page":"367","article-title":"Trabectedin in patients with pre-treated advanced soft tissue sarcoma: a retrospective single center analysis","volume":"15","author":"Kose\u0142a H","year":"2011","unstructured":"Kose\u0142a H , WiaterK, \u015awitajTet al. Trabectedin in patients with pre-treated advanced soft tissue sarcoma: a retrospective single center analysis. Contemp. Oncol. (Pozn)15(6), 367\u2013371 (2011).","journal-title":"Contemp. Oncol. (Pozn)"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.01.006"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000228"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.3390\/md8102647"},{"key":"e_1_3_6_43_1","unstructured":"Wells GA SheaB O\u2019ConnellDet al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses (2022). www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.36741"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100402"},{"issue":"4","key":"e_1_3_6_47_1","doi-asserted-by":"crossref","first-page":"e0227256","DOI":"10.1371\/journal.pone.0227256","article-title":"Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer","volume":"15","author":"Huang Bartlett C","year":"2020","unstructured":"Huang Bartlett C , MardekianJ, CotterMJet al. Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer. PLOS ONE15(4), e0227256 (2020).","journal-title":"PLOS ONE"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:31Z","timestamp":1719125191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":45,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.2217\/fon-2022-0348"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0348","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}